Javier Escobar, M.D., M.Sc.
Name, Degree: Javier I Escobar M.D., M.Sc.
Role(s) in Task Force and Work Group: Member
Institutional Affiliation(s): University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
City, State: New Brunswick, NJ
Biographical Sketch:
Javier I Escobar, M.D., M.Sc.
Member, DSM-V Task Force
Associate Dean for Global Health, University of Medicine & Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey
Dr. Escobar is Associate Dean for Global Health and Professor of Psychiatry and Family Medicine at the University of Medicine and Dentistry of New Jersey–Robert Wood Johnson Medical School. He is the Principal Investigator and Director of the "MUPS Research Center in Primary Care". He is also a member of the National Advisory Committee for the Robert Wood Johnson Foundation's Physicians Faculty Scholars Program. Dr. Escobar served as senior advisor to the Director of the National Institute of Mental Health (NIMH) in 2004 and was a member of NIMH’s National Advisory Mental Health Council. He has been an advisor to the World Health Organization in Geneva, a member of the Food and Drug Administration’s Advisory Committee on Psychiatric Drugs. He has also been a standing member of several research review committees for the National Institutes of Health (NIMH, NIDA, and NIA) and the Veterans Administration, and other national task forces.
Dr. Escobar has been an active researcher in the areas of clinical psychopharmacology, psychiatric epidemiology, psychiatric diagnosis, and cross-cultural medicine and Psychiatry. Currently Dr. Escobar is the principal investigator of two projects funded by the National Institute of Mental Health and also collaborates as mentor, co-investigator or consultant in several other NIH-funded projects in the areas of mental disorders in primary care, treatment of somatoform disorders, cross-cultural psychiatry, psychiatric epidemiology and development and mentoring of new psychiatric researchers. He has published more than 200 scientific articles in national and international books and journals.
Uncompensated affiliations with non-profit or advocacy organizations that may have a direct or indirect interest in psychiatric diagnosis, treatment, or the DSM-V : Three calendar years before nomination and Each year thereafter through the present calendar year. (For 2008, activities to date and commitments for remainder of year.)
|
Non-Profit and Advocacy Organizations |
Year(s) |
Role |
|
American Society of Hispanic Psychiatry |
2005-2007 |
President |
|
NAMI |
2005-2008 |
Scientific Advisory Council |
The two tables below represent Dr. Escobar’s disclosure of significant interests and affiliations for: (1) The time period including the 3 years prior to nomination to serve on the DSM-V Task Force; the calendar year in which nomination to the Task Force occurred; through the calendar year in which the nomination was approved; and (2) the time period including the calendar year after approval, and each successive year to the present.
Dr. Escobar has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed $10,000 in any calendar year.
|
KEY NUMBER:
1. Consultation Fees (include scientific advisory boards)
2. Full- or Part-time Employee
3. Industry-related Grant-Research Support received or pending
4. Honoraria (includes Speakers’ Bureau)
5. Stock or other financial options |
6. Expert testimony
7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)
8. Patents received or pending
9. Officer, director/trustee, executive (specify)
10. Other (specify) |
Disclosure of significant interests including: Three (3) calendar years before nomination, the calendar year of nomination, through the calendar year of approval to serve on the DSM-V Task Force
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
Eli Lilly |
2003-2005 |
1,4 |
|
Pfizer |
2003-2005 |
1, 4 |
|
BMS |
2003-2005 |
1, 4, 5 |
|
Pfizer |
2003-2006 |
1, 4, 5 |
|
Forest |
2003-2005 |
1, 4 |
|
Wyeth |
2003-2005 |
1, 4 |
|
Johnson & Johnson, Bristol-Myers Squibb |
2003- 2005 |
5 |
|
American Association of Geriatric Psychiatry |
2005 |
4 |
Disclosure of significant interests Beginning with the calendar year after APA Board of Trustees approval to serve on the DSM-V Task Force, to the present. (For 2008, activities to date and commitments for remainder of year.)
|
Commercial or Other Organization |
Year(s) |
Key #(s) |
|
NONE |
|
|